

**899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002**

April 15, 2020

10:00 am

OPEN SESSION AGENDA

Board of Pharmacy Mission Statement:

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

Open Session Agenda

Quorum:

Introduction:		
0415-O-01	<u>Approval of the Open Session Meeting Minutes</u> (a) February 6, 2020 (b) March 5, 2020	
<u>Consent Agenda</u>	None	
<u>Executive Director Report</u>	<u>Licensing Report</u> <ul style="list-style-type: none">• Licensing Approval <u>DC Health Updates</u> <ul style="list-style-type: none">• Corona Virus Website – https://coronavirus.dc.gov• Health Notices• Medical Reserve Corps• Health Care Provider Calls• Emergency Legislation and Regulation Communication <u>NABP Updates</u> <ul style="list-style-type: none">• Cancellation of 116th NABP Annual Meeting• NABP Passport (https://nabp.pharmacy/coronavirus-updates/passport/)• Pearson Vue Testing Locations	
0415-O-02	U.S. Department of Health & Human Services (a) Guidance for Licensed Pharmacists, COVID-19 Testing, and Immunity under the PREP Act	
0415-O-03	Handling of Applicant Extension Requests to Test for the North American Pharmacist Licensure Exam (NAPLEX) and the Multistate Pharmacy Jurisdiction Exam (MPJE)	
0415-O-04	Future Board of Pharmacy Meeting Schedules	
<u>Public Comments</u>		

Motion to Adjourn the Open Session	<p>“Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14).” (Roll Call Vote)</p>	
---	---	--

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at __: __

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.

899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002

February 6, 2020

9:42 am - 10:32 am

OPEN SESSION MINUTES

Board of Pharmacy Mission Statement:

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

Open Session Agenda

Quorum: Yes

Introduction:		
0206-O-01	<p><u>Approval of the Open Session Meeting Minutes</u></p> <p>(a) December 5, 2019</p> <p>Motion: Board Member Mr. Alan Friedman moves the Board to approve the December 5, 2019 open session minutes, with two (2) revisions as follows:</p> <ul style="list-style-type: none">➤ On page 8 of the minutes- spell out Death by Dignity instead of using the abbreviation.➤ Update section 1205-O-04 of the minutes to accurately state “The DC Board of Pharmacy will host a strategic planning retreat; at which time the Board will discuss an approach to review and update current regulations over the upcoming three years.” <p>Seconded by: Board Member, Dr. Benjamin Miles</p> <p>Abstentions: None.</p> <p>Motion Carried.</p>	
<u>Consent Agenda</u>	None	
<u>Executive Director Report</u>	<p><u>Licensing Report</u></p> <p><u>Statistical Report on pharmacy professionals in the District of Columbia</u></p> <ul style="list-style-type: none">➤ Pharmacists: 2,150➤ Pharmacists with Vaccination and Immunization Authority: 717➤ Pharmacy Interns: 595➤ Pharmacy Technicians: 966➤ Pharmacy Technician Trainees: 88➤ Pharmacy Technician Training Programs: 12➤ Pharmaceutical Detailers: 937➤ Pharmaceutical Detailer Renewed: 210 <p>Prescription Monitoring Program Update:</p> <p>Dr. White reported that registrants of the Prescription Drug Monitoring Program will receive additional information on webinars that will enhance the knowledge base of all practitioners. She thanked practitioners who participated in the December’s webinars and announced that additional webinars and information about the program are forthcoming.</p>	Dr. Shauna White

Opioid Strategic Plan:

Dr. White reported that further information regarding the Opioid Strategic Plan can found on the Live Long DC website <https://livelong.dc.gov/>.

DC Board of Pharmacy CE Audit Update:

Dr. White reported that the DC Board of Pharmacy is currently undergoing a continuing education audit. She will share statistics with the Board once the audit is concluded.

NARCAN Pilot Program – Free NARCAN at Select DC Pharmacies:

Dr. White reported the following:

- NARCAN is now available at pharmacies throughout the District of Columbia. This medication does not require a prescription and is dispensed to the customer at no cost.
- The Walgreens Pharmacy at Howard University announces that it has dispensed 107 NARCAN kits as of August 30, 2019.
- The pharmacies participating in the pilot program are:

Morgan Pharmacy	3001 P Street NW Washington, DC 20007
Grubbs Pharmacy	326 East Capitol Street NE Washington, DC 20003
Grubbs Pharmacy	1800 Martin Luther King, Jr. Avenue SE Washington, DC 20020
Grubbs Pharmacy	1517 17 th Street NW Washington, DC 20036
Kalorama Pharmacy	1841 Columbia Road NW Washington, DC 20009
Good Care Pharmacy	2910 Martin Luther King Jr. Avenue SE Washington, DC 20032
Excel Pharmacy	3923 South Capitol Street SW Washington, DC 20032
CVS Pharmacy, #22	320 40 th Street NE Washington, DC 20019
CVS Pharmacy, #1340	845 Bladensburg Road NE Washington, DC 20019
CVS Pharmacy, #1360	2834 Alabama Avenue SE Washington, DC 20020
CVS Pharmacy, #1364	6514 Georgia Avenue NW Washington, DC 20012
CVS Pharmacy, #1354	2601 Connecticut Avenue NW Washington, DC 20008
CVS Pharmacy, #2834	3031 14 th Street NW

	<table border="1"> <tr> <td></td> <td>Washington, DC 20009</td> </tr> <tr> <td>Safeway Pharmacy, #1445</td> <td>2845 Alabama Avenue SE Washington, DC 20020</td> </tr> <tr> <td>Walgreens Pharmacy, #15360</td> <td>801 7th Street NW Washington, DC 20001</td> </tr> <tr> <td>Walgreens Pharmacy, #16049</td> <td>Howard University Location 2041 Georgia Avenue NW Washington, DC 20060</td> </tr> <tr> <td>Giant Pharmacy, #384</td> <td>1535 Alabama Avenue SE Washington, DC 20032</td> </tr> <tr> <td></td> <td></td> </tr> </table>		Washington, DC 20009	Safeway Pharmacy, #1445	2845 Alabama Avenue SE Washington, DC 20020	Walgreens Pharmacy, #15360	801 7 th Street NW Washington, DC 20001	Walgreens Pharmacy, #16049	Howard University Location 2041 Georgia Avenue NW Washington, DC 20060	Giant Pharmacy, #384	1535 Alabama Avenue SE Washington, DC 20032			
	Washington, DC 20009													
Safeway Pharmacy, #1445	2845 Alabama Avenue SE Washington, DC 20020													
Walgreens Pharmacy, #15360	801 7 th Street NW Washington, DC 20001													
Walgreens Pharmacy, #16049	Howard University Location 2041 Georgia Avenue NW Washington, DC 20060													
Giant Pharmacy, #384	1535 Alabama Avenue SE Washington, DC 20032													
	<ul style="list-style-type: none"> ➤ The pilot program will continue for six (6) months to one (1) year. ➤ The list of pharmacies participating in the program is published on DC Health’s website and anyone in need of a NARCAN kit should be directed to a participating pharmacy. <p>NABP Annual Meeting:</p> <p>Dr. White reported that the NABP Annual Meeting will be held in Baltimore, MD in May, 2020. Dr. White further reported that Dr. McCants will serve as the delegate to represent the DC Board of Pharmacy.</p> <p>Dr. McCants reported that the DC Board of Pharmacy has about 30% of pharmacists or 1/3 of pharmacists that have vaccination and immunization authorities. Dr. McCants encouraged the public and pharmacy stakeholders to increase the number of immunizing and vaccinating Pharmacists to expand the role of Pharmacists.</p>													
<u>Assistant General Counsel Report</u>	None	Ms. Carla Williams												
<u>Subcommittee Reports</u>														
0206-O-02	<p><u>Legislative and Regulatory Subcommittee Report</u></p> <p>Mr. Friedman reported that the Legislative and Regulatory Committee would undertake a comprehensive review of the current Pharmacy regulations and attempt to update them to current practice. Mr. Friedman further reported that at the retreat, the subcommittee began the reviews of chapter 65 (DCMR for pharmacists), chapter 83 (DCMR for pharmaceutical detailers), chapter 99 (DCMR for pharmacy technicians); as well as chapter 100 (Collaborative Practice Agreements between Physicians and Pharmacists).</p>	Mr. Alan Friedman												
0206-O-03	<p><u>Communications Subcommittee Report</u></p> <p>Dr. McCants reported the Communications Subcommittee Chair, Dr. Ashley Bow, as absent and on maternity leave.</p>	Dr. McCants												

	<p>Dr. McCants further reported the activities of the all-day DC Board of Pharmacy Retreat, which was held in December 2019. As such, she reported that the retreat carved out the framework of a three-year strategic plan for the DC Board of Pharmacy. Dr. McCants surmises that the strategic plan will be published after a Board review and approval. The following topics are among others that were addressed at the retreat:</p> <ul style="list-style-type: none"> ➤ Review and expansion of the DC Board of Pharmacy Regulations. ➤ Relationship and communication cohesiveness with pharmaceutical detailers, pharmacists, pharmacy technicians, and pharmacy interns through invitations to attend DC Board of Pharmacy meetings. 	
0206-O-04	<p>Student Presentation – Summary of NABP News</p> <p>Pharmacy Intern, Gerlynn Calvaire gave a summary of the NABP E-Newsletters.</p>	
NABP E-Newsletter	<p><u>January 15, 2020</u></p> <p>NABP Seeks Committee and Task Force Volunteers.</p> <p>Former Doctor Pleads Guilty in Conspiracy to Unlawfully Sell Prescription Drugs Through Rogue Internet Pharmacy Organization.</p> <p>Mylan Recalls Three Lots of Nizatidine Capsules Due to NDMA Impurities.</p> <p>January 28 FDA Drug Topics Webinar to Address Funding Opportunities to Reduce Preventable Harm.</p> <p><u>January 09, 2020</u></p> <p>NASEM Report Recommends Framework for Opioid Prescribing Guidelines for Acute Pain.</p> <p>Policy Perspectives: Impact of CBD-Derived Products on State Boards of Pharmacy.</p> <p>Aurobindo Pharma Issues Mirtazapine Recall Due to Dosage Label Error.</p> <p>Pharmacists Continue to Be Seen as Trustworthy, According to Latest Gallup Poll Results.</p> <p>Reminder: Social Media Kit Available to Help Pharmacists Educate Consumers About Drug Safety.</p> <p>Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: https://nabp.pharmacy/newsroom/news/.</p>	Dr. Tamara McCants

<p>Public Comments</p>	<p>Ositadinma Akaemg, Chief Medical Director for HASTA/DC Health spoke on expanding Expedited Partner Therapy (EPT) to stop the spread of sexually transmitted diseases (STDs) and improve the health of District residents. EPT is the clinical practice of treating the sex partners of patients diagnosed with Chlamydia by providing prescriptions or medications to the patient to take to his/her partner(s) without the health care provider first examining the partner. Mr. Akaemg expressed that EPT is a safe, quick and convenient way to treat Chlamydia.</p> <p>Mr. Akaemg reported that it has been shown through research that Expedited Partner Therapy helps to address high rates of chlamydia and gonorrhea. Mr. Akaemg further reported that Expedited Partner Therapy can help reduce the risk of reinfection rates as well. Mr. Akaemg proposed a potential joint letter with HASTA that can be released to actively practicing DC Pharmacists informing them specifically about Expedited Partner Therapy (EPT) because of the knowledge gap observed by HASTA.</p> <p>Dr. White encouraged Mr. Akaemg to present this matter to DC Board of Medicine as well. The DC Board of Pharmacy expressed consideration of a partnership in expanding knowledge of Expedited Partner Therapy (EPT). The DC Board of Pharmacy is looking forward to learning more about the program by inviting Mr. Akaemg to conduct a presentation before the Board at the next scheduled open session meeting.</p>	
<p>Motion to Adjourn the Open Session</p>	<p>Board member, Mr. Benjamin Miles moves as follows:</p> <p>“Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14).” (Roll Call Vote)</p> <p>Seconded by: Board Member, Mr. Alan Friedman</p> <p>Roll Call Vote: Dr. Tamara McCants: Votes in favor of the motion. Dr. Benjamin Miles: Votes in favor of the motion. Mr. Gregory Cendana: Votes in favor of the motion. Abstentions: None Motion Carried</p>	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at 10:32 am

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.

899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002

March 5, 2020

9:30 AM – 9:31 AM

OPEN SESSION MINUTES

Board of Pharmacy Mission Statement:

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

Open Session Agenda

Quorum: Yes

Introduction:	
Consent Agenda	None
Motion to Adjourn the Open Session	<p>Board member, Mr. Alan Friedman moves as follows:</p> <p>“Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14).”</p> <p>Seconded by: Board Member, Dr. Benjamin Miles.</p> <p>Roll Call Vote: Dr. Tamara McCants: Votes in favor of the motion. Mr. Alan Friedman: Votes in favor of the motion. Dr. Ashlee Bow: Votes in favor of the motion. Dr. Benjamin Miles: Votes in favor of the motion. Ms. Chikita Sanders: Votes in favor of the motion.</p> <p>Abstentions: None Motion Carried</p>

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at 9:31 AM



Guidance

U.S. Department of Health & Human Services
Office of the Assistant Secretary for Health
Wednesday, April 8, 2020

Guidance for Licensed Pharmacists, COVID-19 Testing, and Immunity under the PREP Act

On January 31, 2020, the Secretary of Health and Human Services declared that the 2019 novel coronavirus (COVID-19) is a public-health emergency for the United States. The United States Department of Health and Human Services (HHS) is the lead agency for the federal government's response to the COVID-19 pandemic.

A key component of that response is rapidly expanding COVID-19 testing across America. Within HHS, the Office of the Assistant Secretary for Health leads federal efforts to support that expansion.

Pharmacists, in partnership with other healthcare providers, are well positioned to aid COVID-19 testing expansion. Pharmacists are trusted healthcare professionals with established relationships with their patients. The vast majority of Americans live close to a retail or independent community-based pharmacy. That proximity reduces travel to testing locations, which is an important mitigation measure. Pharmacists also have strong relationships with medical providers and hospitals to appropriately refer patients when necessary.

Therefore, as an Authority Having Jurisdiction under the Secretary's March 10, 2020 declaration under the Public Readiness and Emergency Preparedness Act (PREP Act), OASH issues this guidance authorizing licensed pharmacists to order and administer COVID-19 tests, including serology tests, that the Food and Drug Administration (FDA) has authorized. *See* 85 Fed. Reg. 15,198, 15,202 (March 17, 2020); *see also* Pub. L. No. 109-148, Public Health Service Act § 319F-3, 42 U.S.C. § 247d-6d and 42 U.S.C. § 247d-6e.¹ By doing so, such pharmacists will qualify as "covered persons" under the PREP Act. And they may receive immunity under the PREP Act with respect to all claims for loss caused by, arising out of, relating to, or resulting from, the administration or use of FDA-authorized COVID-19 tests. 42 U.S.C. § 247d-6d(a)(1).

¹ FDA's Emergency Use Authorizations for diagnostic and therapeutic medical devices to diagnose and respond to particular public health emergencies are available [here](#).

² This guidance does not speak to or change reimbursement policy whether a licensed pharmacist may obtain reimbursement from a government or private payer for ordering or administering an FDA-authorized test.